Remibrutinib

Overview

Remibrutinib, is a potent and orally active bruton tyrosine kinase ( BTK ) inhibitor with an IC 50 value of 1 nM. Remibrutinib inhibits BTK activity with an IC 50 value of 0.023 μM in blood. Remibrutinib has the potential for Chronic urticaria (CU) treatment.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Btk

Product Information

• Catalog No.: HY-128757
• CAS No.: 1787294-07-8
• Molecular Formula: C27H27F2N5O3
• Molecular Weight: 507.53
• Purity: 99.76%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (4.10 mM); Clear solution
• Availability: In-stock

Source

Original product source